NEK1 Promotes Ovarian Cancer Progression via p53 Suppression While Enhancing Sensitivity to Genotoxic Therapy
Huiyang Song, Xia Wang, Aiqing Yang, Xuejiao Ren, Xiaoqi Zhou, Yifei Qiu, Yating Cai, Chengming Gao, Gangqiao Zhou, Pengbo Cao · 2026
Read NEK1 Promotes Ovarian Cancer Progression via p53 Suppression While Enhancing Sensitivity to Genotoxic Therapy by Huiyang Song, Xia Wang, Aiqing Yang, Xuejiao Ren, Xiaoqi Zhou, Yifei Qiu, Yating Cai, Chengming Gao, Gangqiao Zhou, Pengbo Cao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13206693.txt.
Description
Song and a team of colleagues pinned down a dual role for a cell-cycle kinase in ovarian cancer in twenty twenty-six. Ovarian cancer spreads and recurs readily, with few treatment options. The kinase NEK1 helps manage the cell cycle and DNA damage responses and is linked to several cancers, but its ovarian role was unclear.
Experiments in cells and animals showed NEK1 drives tumor growth. It works by suppressing the guardian protein p53, lowering its downstream enforcers and thereby weakening cell-cycle arrest and cell death; without p53 protein present, NEK1's effect vanished. High NEK1 in patients tracked with poorer prognosis across cohorts. Paradoxically, high NEK1 also made tumors more sensitive to radiation, because p53-mediated repair was impaired. The authors propose NEK1 as a prognostic marker and a guide for DNA-damaging therapy choices.
Catalog record
| CREATOR | Huiyang Song, Xia Wang, Aiqing Yang, Xuejiao Ren, Xiaoqi Zhou, Yifei Qiu, Yating Cai, Chengming Gao, Gangqiao Zhou, Pengbo Cao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |